Treatment Information

Back

Liver Cancer treatment details. Chemotherapy.

Chang Gung Memorial Hospital, Taipei, Taiwan Region.

Survival: monthsCountry:Taiwan Region
Toxiciy Grade:4City/State/Province:Taipei
Treatments:ChemotherapyHospital:Chang Gung Memorial Hospital
Drugs:Journal:Link
Date:Nov 2002

Description:

Patients: This Phase I-II study involved 50 patients with advanced hepatocellular (liver) carcinoma who had not received chemotherapy before. Thirty-five patients entered the Phase II portion of the study.

Treatment: Treatment consisted of two chemotherapy agents – gemcitabine (gemzar) and doxorubicin (adriamycin). The Phase I part of the study involved dose escalation.

Toxicity: For Phase I at the highest dosage levels, grade 3-4 toxicities included: hematological (leucopenia, neutropenia, anemia, and thrombocytopenia) and non-hematological (i.e. mucositis, liver, neutropenic fever, and infection). For Phase II, grade 4 toxicities included: hematological (leucopenia, neutropenia, anemia, and thrombocytopenia) and non-hematological (i.e. mucositis, liver, neutropenic fever, and infection).

Results: The median survival was 4.6 months for all patients.

Support: This study was sponsored by Eli Lilly and Company. Eli Lilly markets gemcitabine

Correspondence: Dr. Cheng-Hsu Wang




Back